MedTrace Logo

SARS-CoV-2 Donor-Recipient Immunity Transfer

NCT04666025 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2024-04-08

No results posted yet for this study

Summary

This study investigates whether donors with previous exposure to COVID-19 can pass their immunity by hematopoietic (blood) stem cell transplant (HCT) donation to patients that have not been exposed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes the COVID19 infection. This study may provide critical information for medical decision-making and possible immunotherapy interventions in immunocompromised transplant recipients, who are at high risk for COVID19 severe illness.

Conditions

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of nasopharyngeal swabs, blood, and saliva samples

OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

OTHER

Electronic Health Record Review

Medical charts are reviewed

OTHER

Questionnaire Administration

Complete questionnaire

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Monzr M Al Malki · City of Hope Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2023-05-05
Completion
2023-05-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04666025 on ClinicalTrials.gov